Innovative Zalunfiban Treatment Promises Reduced Heart Attack Risks at First Contact CeleCor Therapeutics' zalunfiban shows promise in reducing severe heart damage risks in heart attack patients, improving blood flow significantly.

Innovative Zalunfiban Treatment Promises Reduced Heart Attack Risks at First Contact #United_States #New_Orleans #CeleCor #HEART_ATTACK #Zalunfiban

CeleCor Therapeutics Reports Positive Results of Phase 3 Trial for Heart Attack Drug Disaggpro CeleCor Therapeutics has announced positive primary results from its Phase 3 trial for Disaggpro™, a new anti-platelet drug aimed at heart attack treatment.

CeleCor Therapeutics Reports Positive Results of Phase 3 Trial for Heart Attack Drug Disaggpro #United_States #Del_Mar #CeleCor #Disaggpro #heart-attack

CeleCor Therapeutics Advances Heart Attack Treatment with Disaggpro in Phase 3 Study Completion CeleCor Therapeutics has finished its multinational Phase 3 trial of Disaggpro, an innovative drug aimed at treating heart attacks swiftly at the initial medical contact.

CeleCor Therapeutics Advances Heart Attack Treatment with Disaggpro in Phase 3 Study Completion #United_States #Del_Mar #CeleCor #Disaggpro #STEMI